Search Within

Joseph Patrick Erinjeri

Formats
  1. Journal Article (134)
  2. Meeting Abstract (58)
  3. Book Section (5)
  4. Review (4)
  5. Research Letter (2)
  6. Correspondence (1)
  7. Editorial (1)
  8. Guidelines (1)
Groups
  1. Interventional Radiology Service (206)
  2. Radiology, Department of (206)
  3. Center for Pancreatic Cancer Research (128)
  4. Department of Medicine (91)
  5. Solid Tumor Oncology Division (87)
  6. Sloan Kettering Institute Postdocs (61)

More Groups

People
  1. Stephen Solomon (91)
  2. Constantinos Sofocleous (65)
  3. Hooman Yarmohammadi (61)
  4. Etay Ziv (48)
  5. Karen Brown (37)
  6. Anne Covey (34)

More People

Years
  1. 2025 (10)
  2. 2024 (24)
  3. 2023 (21)
  4. 2022 (26)
  5. 2021 (5)
  6. 2020 (14)

More Years

Publications
  1. Journal of Vascular and Interventional Radiology (46)
  2. Journal of Clinical Oncology (28)
  3. CardioVascular and Interventional Radiology (15)
  4. Radiology (10)
  5. Annals of Oncology (6)
  6. Clinical Cancer Research (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (53)
  2. Springer (35)
  3. American Society of Clinical Oncology (32)
  4. Radiological Society of North America, Inc. (10)
  5. American Association for Cancer Research (6)
  6. Oxford University Press (6)

More Publishers

Results (206)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kudo, M.; Lencioni, R.; Erinjeri, J. P.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V.; Bouattour, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • safety analysis by treatment periods from Emerald-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma
    Meeting Abstract

    Chan, S.; Sangro, B.; Kudo, M.; Erinjeri, J.; Qin, S. K.; Ren, Z. G.; Arai, Y.; Breder, V.; Lin, S. M.; Peron, J. M.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • Outcomes by baseline liver function in Emerald-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma
    Meeting Abstract

    Chan, S.; Decaens, T.; Kudo, M.; Erinjeri, J.; Lencioni, R.; Bouattour, M.; Breder, V.; Heo, J.; Mazzaferro, V.; Park, J. W.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Kudo, M.; Erinjeri, J.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; more...
    Journal of Hepatology (2024)

    Fulltext@MSK | Save
  • mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with or without bevacizumab in participants with embolization-eligible hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Penagos, F. E.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Immunotherapy and transarterial embolization in patients with metastatic melanoma: A retrospective cohort study
    Journal Article

    Haghani, L.; Zhan, C.; Yarmohammadi, H.; Ziv, E.; Sotirchos, V. S.; Sarkar, D.; Shoushtari, A. N.; Erinjeri, J. P.
    Immunotherapy (2024)

    Fulltext@MSK | Save
  • EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization
    Meeting Abstract

    Lencioni, R.; Kudo, M.; Erinjeri, J.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save